Innate Pharma Files 6-K, Announces Press Release
Ticker: IPHYF · Form: 6-K · Filed: May 6, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Innate Pharma dropped a 6-K on May 6th, likely with news in the attached press release.
AI Summary
Innate Pharma SA filed a Form 6-K on May 6, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates Innate Pharma is making a public announcement, which could contain material information for investors. Investors should review the referenced press release for details.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no new financial data or significant operational changes detailed within the 6-K itself.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- May 6, 2025 (date) — Filing date and press release date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release dated May 6, 2025, as required for foreign private issuers.
What is the filing date of this report?
The filing date of this report is May 6, 2025.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
Does Innate Pharma file annual reports under Form 20-F or 40-F?
Innate Pharma indicates it files annual reports under Form 20-F, as shown by the checkmark next to 'Form 20-F'.
What is the address of Innate Pharma's principal executive office?
The address of Innate Pharma's principal executive office is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 6, 2025 regarding Innate Pharma SA (IPHYF).